Rare variants lowering the levels of coagulation factor X are protective against ischemic heart disease

Elvezia Maria Paraboschi, Amit Vikram Khera, Piera Angelica Merlini, Laura Gigante, Flora Peyvandi, Mark Chaffin, Marzia Menegatti, Fabiana Busti, Domenico Girelli, Nicola Martinelli, Oliviero Olivieri, Sekar Kathiresan, Diego Ardissino, Rosanna Asselta, and Stefano Duga

Disclosures: F.P. Consultancy: Kedrion, LFB; Member of Advisory Board: Ablynx; Speaker at Educational meetings: Ablynx, Alnylam, Roche, Shire, Sobi, Bayer, Novo Nordisk, Bayer, Grifols.

Contributions: EMP, AVK, MC, RA performed biostatistical and genetic analyses; FP and MM carried out functional and antigen level measurements; FP, PAM, FB, DG, NM, OO, and DA enrolled the patients in the study, collected the clinical history, and evaluated the clinical phenotypes. SD and SK conceived and supervised the entire study, and participated in the analysis and interpretation of data; EMP and RA wrote the manuscript.